Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MO-TRANS: Mocravimod in Adult AML Patients Undergoing Allogeneic HCT
NCT05429632Phase 3Recruiting
- Sponsor
- Priothera
- Start
- Jun 2022
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial of mocravimod in acute myeloid leukemia (AML) (3 arms), sponsored by Priothera. Primary endpoint: Relapse-Free Survival at 12 months. Started Jun 2022; status: recruiting.
02
Drugs
mocravimod
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05429632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05429632.